FINAL PROGRAM www.essm.org 10th Congress of the European ...
FINAL PROGRAM www.essm.org 10th Congress of the European ...
FINAL PROGRAM www.essm.org 10th Congress of the European ...
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
scientific program, Tuesday, 27 November 2007MP-04-130New selection criteria for surgicaltreatment <strong>of</strong> Peyronie‘s diseaseMariano Rossello, SpainA. Mus, G. CondeC-05 Instructional Course14.30 - 16.00 Auditorium IITestosterone Replacement – “Starting with <strong>the</strong>patient”tChairperson: John Dean, United KingdomGe<strong>of</strong>frey Hackett, United KingdomUsing “real patient” case studies from hospital andprimary care, this course <strong>of</strong>fers a practical guide toidentifying, counselling and treating patients with testosteronedeficiency. It will explore testosterone bothin Sexual Medicine and in <strong>the</strong> broader issues <strong>of</strong> men’shealth. Participants will be asked to join in <strong>the</strong> decision-makingprocess, testing <strong>the</strong>ir own knowledgeand developing <strong>the</strong>ir skills in this important issue.16.00 - 16.30 C<strong>of</strong>fee breakR-01 Round Table16.30 - 18.00 Auditorium VI/VIIErection – a predictive <strong>of</strong> subsequent health/ED– a predictive <strong>of</strong> subsequent diseaseChairperson: Siegfried Meryn, AustriaR-01-01R-02-02R-01-03The cardiac urologist or urologicalcardiologistPiero Montorsi, ItalyPremonitory sign <strong>of</strong> metabolicanomalitiesSiegfried Meryn, AustriaTestosterone, erectile function andlinks to o<strong>the</strong>r health-risk factors?Claude Schulman, BelgiumP-06 Podium Session16.30 - 18.00 Room 3PharmacologyChairpersons: Ian Eardley, United KingdomPetter Hedlund, SwedenP-06-051P-06-052P-06-053P-06-054Phase IIb efficacy and safety <strong>of</strong>bremelanotide in <strong>the</strong> treatment <strong>of</strong>non-diabetic males with erectiledysfunctionStanley E. Alth<strong>of</strong>, USASafety and efficacy <strong>of</strong> orally inhaledapomorphine (VR004) in <strong>the</strong> treatment<strong>of</strong> erectile dysfunctionFrazer M<strong>org</strong>an, United KingdomA. Riley, M. MainLong-term safety and efficacy <strong>of</strong>5 mg tadalafil dosed once daily inmen with erectile dysfunctionHartmut Porst, GermanyJ. Rajfer, A. Casabe, R. Feldman,D. Ralph, L. Vieiralves, A. Esler, S. KliseWhat characteristics are associatedwith phosphodiesterase type5 inhibitor adverse events?Classification and regression treeanalyses in 3488 tadalafil-treatedmen with erectile dysfunctionGerald Brock, CanadaS. Glina, I. Moncada, S. Watts, L. Xu,V. KopernickyP-06-055 Efficacy and safety <strong>of</strong> oralmirodenafil in <strong>the</strong> treatment <strong>of</strong>men with erectile dysfunction: amulti-center, randomized, doubleblind, placebo-controlled, fixeddose, parallel group clinical trialJae-Seung Paick, Republic <strong>of</strong> KoreaH.-K. Choi, S.-C. Kim, J.-K. Suh, T.-Y.Ahn, J.-J. Kim, J.-K. Park, W.-S. Chung,K.-S. Park, S.-W. Lee, D.-Y. Yang,S.-W. Kim, K.-S. Min, K.-H. Moon,N.-C. ParkR-01-04Penis, prostate and PDE5Kevin T. McVary, USA35
Change language